Physicochemical characterization of a novel graphene-based magnetic resonance imaging contrast agent

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 2821-2833

  Kanakia, Shruti ^a   Toussaint, Jimmy D ^a   Mullick Chowdhury, Sayan ^a   Lalwani, Gaurav ^a   Tembulkar, Tanuf ^a   Button, Terry ^a,b   Shroyer, Kenneth R ^b   Moore, William ^b   Sitharaman, Balaji ^a  

^a St Francis Hospital The Heart Center   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Contrast agent; Dextran; Graphene; Magnetic resonance imaging; Manganese; Physicochemical properties; Preclinical; Relaxivity

Indexed keywords

DEIONIZED WATER; DEXTRAN; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GRAPHENE OXIDE; MANGAFODIPIR; MANGANESE; MANGANESE ION INTERCALATED GRAPHENE OXIDE NANOPLATELET FUNCTIONALIZED WITH DEXTRAN; MANNITOL; MULTI HANCE; NANOMATERIAL; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; UNCLASSIFIED DRUG; WATER;

ADSORPTION; ALLERGIC REACTION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; DRUG SYNTHESIS; HISTAMINE RELEASE; HYDROPHILICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSMOLALITY; PARTITION COEFFICIENT; PROTEIN BINDING; SOLUBILITY; THERMOSTABILITY; VISCOSITY;

CONTRAST AGENT; DEXTRAN; GRAPHENE; MAGNETIC RESONANCE IMAGING; MANGANESE; PHYSICOCHEMICAL PROPERTIES; PRECLINICAL; RELAXIVITY;

CONTRAST MEDIA; DEXTRANS; GADOLINIUM; GRAPHITE; MAGNETIC RESONANCE IMAGING; MANGANESE; NANOSTRUCTURES; PHANTOMS, IMAGING; PHYSICOCHEMICAL PHENOMENA; THERMOGRAVIMETRY;

EID: 84881304897     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S47062     Document Type: Article

References (49)

1. Sitharaman B, Wilson LJ. Gadofullerenes and gadonanotubes: a new paradigm for high-performance magnetic resonance imaging contrast agent probes. J Biomed Nanotechnol. 2007;3(4):342-352.
2. Pan D, Caruthers SD, Senpan A, Schmieder AH, Wickline SA, Lanza GM. Revisiting an old friend: manganese-based MRI contrast agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3(2):162-173.
3. Ananta JS, Godin B, Sethi R, et al. Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol. 2010;5(11):815-821.
4. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol. 2008;66(2):230-234.
5. Bayer HealthCare Pharmaceuticals Inc, Bracco Diagnostics Inc, GE Healthcare, Mallinkrodit Inc Important Drug Warning for Gadoliniumbased Contrast Agents [letter to healthcare professionals]. Bayer HealthCare Pharmaceuticals Inc, Bracco Diagnostics Inc, GE Healthcare, Mallinkrodit Inc; 2007. Available from: http://www.fda.gov/downloads/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm154532.pdf. Accessed June 18, 2013.
6. Feng L, Liu Z. Graphene in biomedicine: opportunities and challenges. Nanomedicine (Lond). 2011;6(2):317-324.
7. Paratala BS, Jacobson BD, Kanakia S, Francis LD, Sitharaman B. Physicochemical characterization, and relaxometry studies of micrographite oxide, graphene nanoplatelets, and nanoribbons. PLoS One. 2012;7(6):e38185.
8. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40(11):715-724.
9. Vogler H, Platzek J, Schuhmann-Giampieri G, et al. Pre-clinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging. Eur J Radiol. 1995;21(1):1-10.
10. ICH. Safety pharmacology studies for human pharmaceuticals. Geneva: International Conference on Harmonisation; 2000. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf. Accessed July 15, 2013.
11. US FDA. Developing medical imaging drug and biological products part 1: conducting safety assessments. Rockville: US Food and Drug Adminsitration; 2004. Available from: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071600.pdf. Accessed July 15, 2013.
12. OECD. OECD guidelines for the testing of chemicals. Paris: Organisation for Economic Co-operation and Development; 2000. Available from: http://www.oecd.org/chemicalsafety/testing/2731134.pdf. Accessed July 15, 2013.
13. Runge VM. Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging. 2000;12(2):205-213.
14. Zhang S, Yang K, Feng L, Liu Z. In vitro and in vivo behaviors of dextran functionalized graphene. Carbon. 2011;49(12):4040-4049.
15. Sirlin CB, Vera DR, Corbeil JA, Caballero MB, Buxton RB, Mattrey RF. Gadolinium-DTPA-dextran: a macromolecular MR blood pool contrast agent. Academic Radiology. 2004;11(12):1361-1369.
16. Feridex IV (ferumoxides injectable solution) [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals Inc; 2007. Available from: http://www.amagpharma.com/documents/products/pdfs/feridex_insert.pdf. Accessed June 18, 2013.
17. Martwiset S, Koh AE, Chen W. Nonfouling characteristics of dextrancontaining surfaces. Langmuir. 2006;22(19):8192-8196.
18. Stankovich S, Dikin DA, Piner RD, et al. Synthesis of graphene-based nanosheets via chemical reduction of exfoliated graphite oxide. Carbon. 2007;45(7):1558-1565.
19. Tang M, Dou H, Sun K. One-step synthesis of dextran-based stable nanoparticles assisted by self-assembly. Polymer. 2006;47(2):728-734.
20. Zatz JL. Physical stability of suspensions. J Soc Cosmet Chem. 1985;36(6):393-411.
21. Tweedle MF. The ProHance story: the making of a novel MRI contrast agent. Eur Radiol. 1997;7 Suppl 5:225-230.
22. Hummers WS Jr, Offeman RE. Preparation of graphitic oxide. J Am Chem Soc. 1958;80(6):1339.
23. Shan C, Yang H, Han D, Zhang Q, Ivaska A, Niu L. Water-soluble graphene covalently functionalized by biocompatible poly-L-lysine. Langmuir. 2009;25(20):12030-12033.
24. Liu Z, Robinson JT, Sun X, Dai H. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J Am Chem Soc. 2008;130(33): 10876-10877.
25. Kim YK, Kim MH, Min DH. Biocompatible reduced graphene oxide prepared by using dextran as a multifunctional reducing agent. Chem Commun (Camb). 2011;47(11):3195-3197.
26. Deray G, Jacobs C. Are low osmolality contrast media less nephrotoxic? Nephrol Dial Transplant. 1996;11(6):930-931.
27. American Society of Health-System Pharmacists. Quick Guide to Contrast Media. Bethesda, MD: Contrast Media and Medication Management Standard Resource Center; 2010.
28. Pugh ND. Haemodynamic and rheological effects of contrast media: the role of viscosity and osmolality. Eur Radiol. 1996;6 Suppl 2: S13-S15.
29. Voeltz MD, Nelson MA, McDaniel MC, Manoukian SV. The important properties of contrast media: focus on viscosity. J Invasive Cardiol. 2007;19(3):1A-9A.
30. Lancelot E, Idée JM, Laclédère C, Santus R, Corot C. Effects of two dimeric iodinated contrast media on renal medullary blood perfusion and oxygenation in dogs. Invest Radiol. 2002;37(7):368-375.
31. Caravan P. Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action. Acc Chem Res. 2009;42(7):851-862.
32. van Liempd S, Morrison D, Sysmans L, Nelis P, Mortishire-Smith R. Development and validation of a higher-throughput equilibrium dialysis assay for plasma protein binding. J Lab Autom. 2011;16(1):56-67.
33. Rimkus G, Bremer-Streck S, Grüttner C, Kaiser WA, Hilger I. Can we accurately quantify nanoparticle associated proteins when constructing high-affinity MRI molecular imaging probes? Contrast Media Mol Imaging. 2011;6(3):119-125.
34. Watts DL. The nutritional relationships of manganese. J Orthomol Med. 1990;5(4):219-222.
35. Sullivan JF, Blotcky AJ, Jetton MM, Hahn HK, Burch RE. Serum levels of selenium, calcium, copper magnesium, manganese and zinc in various human diseases. J Nutr. 109(8):1432-1437.
36. Aschner M, Aschner JL. Manganese neurotoxicity: cellular effects and blood-brain barrier transport. Neurosci Biobehav Rev. 1991;15(3): 333-340.
37. Morcos SK, Thomsen HS, Webb JA Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR). Dialysis and contrast media. Eur Radiol. 2002;12(12):3026-3030.
38. Prince MR, Zhang H, Zou Z, Staron RB, Brill PW. Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol. 2011;196(2):W138-W143.
39. Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC. Allergic-like breakthrough reactions to gadolinium contrast agents after corticosteroid and antihistamine premedication. AJR Am J Oroentgenol. 2008;190(1): 187-190.
40. Kuefner MA, Feurle J, Uder M, Bautz W, Schwelberger HG. Influence of magnetic resonance contrast media on the activity of histamine inactivating enzymes. Acad Radiol. 2009;16(3):358-362.
41. ProHance® (gadoteridol) injection, solution [product label]. Princeton, NJ: Bracco Diagnostics Inc; nd. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=778aee03-07d4c-481a-be8a-a75db0702f5a. Accessed June 18, 2013.
42. MultiHance - gadobenate dimeglumine injection, solution [highlights of prescribing information]. Princeton, NJ: Bracco Diagnostics Inc; nd. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e56fd303-309e0c-490b-8f31-64fc267b4df5. Accessed June 18, 2013.
43. Magnevist® (brand of gadopentetate dimeglumine) [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; 2011. Available from: http://labeling.bayerhealthcare.com/html/products/pi/Magnevist_PI.pdf. Accessed June 18, 2013.
44. Teslascan data sheet [webpage on the Internet]. Portland: RxList Inc.; 2009. Available from: http://www.rxlist.com/teslascan-drug.htm. Accessed July 15, 2013.
45. Optimark [package insert]. Hazelwood, MO: Mallinckrodt; nd. Available from: http://www.mallinckrodt.com/webforms/threecolumn.aspx?id=497. Accessed June 18, 2013.
46. Omniscan™ (gadodiamide) injection [product label]. Princeton, NJ: GE Healthcare; 2011. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e9a37e2-f28a-4373-bf0f-3e9b60f42d8a. Accessed July 15, 2013.
47. Kobayashi H, Brechbiel MW. Dendrimer-based macromolecular MRI contrast agents: characteristics and application. Mol Imaging. 2003;2(1):1-10.
48. Yang K, Hu L, Ma X, et al. Multimodal imaging guided photothermal therapy using functionalized graphene nanosheets anchored with magnetic nanoparticles. Adv Mater. 2012;24(14):1868-1872.
49. Sitharaman B, Wilson LJ. Gadonanotubes as new high-performance MRI contrast agents. Int J Nanomedicine. 2006;1(3):291-295.